Elevance Health, Inc.

Name: Elevance Health, Inc. standardized financial statements, quarterly
Creator: Listed

ELVNYSECIK 1156039FinancialsFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$51.43bn, Q3 FY2026

Operating income$1.27bn, Q3 FY2026

Net income$1.36bn, Q3 FY2026

Elevance Health, Inc., income statement, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Revenue	$bn	42.6	42.6	43.9	45.1	45.4	48.9	49.8	50.7	49.7	50.2	50.5	51.4
Cost of revenue	$bn	4.8	3.8	4.8	5.1	6.0	5.0	5.3	5.4	5.5	5.5	5.5	5.6
Selling, general and administrative	$bn	5.0	4.9	5.1	5.3	4.8	5.3	5.0	5.3	5.4	6.3	5.5	5.8
Operating income	$bn	1.3	3.0	2.8	1.4	0.7	3.2	2.4	1.3	0.3	2.1	1.8	1.3
Interest expense	$bn	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4
Income tax	$bn	0.2	0.7	0.7	0.4	0.2	0.6	0.5	0.2	(0.3)	0.5	0.5	0.5
Net income	$bn	0.9	2.2	2.3	1.0	0.4	2.2	1.7	1.2	0.5	1.8	1.5	1.4
Diluted EPS	$ per share	not reported	9.59	9.85	4.36	not reported	9.61	7.72	5.32	not reported	8.00	6.71	6.27
Basic EPS	$ per share	not reported	9.65	9.91	4.38	not reported	9.64	7.74	5.32	not reported	8.03	6.74	6.30

Balance sheet

Cash and equivalents$10.35bn, Q3 FY2026

Long-term debt$30.38bn, Q3 FY2026

Shareholders' equity$44.68bn, Q3 FY2026

Elevance Health, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Cash and equivalents	$bn	6.5	6.2	6.5	7.9	8.3	7.5	8.6	8.7	9.5	9.7	10.2	10.3
Current assets	$bn	60.0	60.9	62.3	62.8	58.9	61.1	63.3	63.8	63.0	67.0	67.2	68.5
Total assets	$bn	109	112	113	117	117	120	122	123	121	126	126	128
Current liabilities	$bn	41.8	44.3	41.8	42.0	40.6	42.7	43.8	40.9	41.0	45.3	44.3	46.7
Total liabilities	$bn	69.5	71.2	70.7	72.7	75.5	77.1	78.1	78.7	77.5	81.8	81.4	83.0
Long-term debt	$bn	23.2	22.0	24.6	24.7	29.2	28.1	28.2	31.2	30.8	30.8	30.7	30.4
Current portion of debt	$bn	1.6	2.9	2.9	2.1	1.6	1.6	1.6	0.7	1.1	0.4	0.4	0.4
Short-term borrowings	$bn	0.2	1.6	0.2	0.4	0.4	0.3	0.4	0.2	0.2	0.7	0.0	0.0
Shareholders' equity	$bn	39.3	40.6	42.2	43.8	41.3	42.5	43.7	44.0	43.9	43.9	44.9	44.7

Cash flow

Operating cash flow$1.27bn, Q3 FY2026

Capital expenditure$267.0m, Q3 FY2026

Share repurchases$330.0m, Q3 FY2026

Elevance Health, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Operating cash flow	$m	(2,971)	1,978	447	2,677	706	1,017	2,054	1,135	84.0	4,332	1,913	1,267
Capital expenditure	$m	326	279	323	332	322	196	267	360	293	235	287	267
Dividends paid	$m	346	379	378	386	373	386	385	381	377	376	373	373
Share repurchases	$m	928	566	463	60.0	1,811	880	378	876	471	1,124	234	330

Diluted shares (weighted)217.60m, Q3 FY2026

Elevance Health, Inc., shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Diluted shares (weighted)	m shares	240	238	237	234	233	233	227	226	224	220	218	218

Shares outstanding: 216.06m at Oct 15, 2026, from the cover of the 10-Q filed Oct 21, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.